VentriPoint Diagnostics Ltd., a Canadian health care equipment and supply company, has been making significant strides in the field of heart disease diagnostics. Based in Calgary, the company is listed on the TSX Venture Exchange and specializes in the development of innovative diagnostic equipment. VentriPoint’s primary focus is on creating three-dimensional models and critical measurements from images captured by existing devices, enhancing the accuracy and efficiency of heart disease diagnosis.

As of October 26, 2025, VentriPoint’s stock closed at CAD 0.1, reflecting a market capitalization of CAD 17,530,000. The company’s stock has experienced fluctuations over the past year, reaching a 52-week high of CAD 0.2 on March 24, 2025, and a low of CAD 0.08 on February 25, 2025. Despite these variations, VentriPoint continues to be a notable player in the health care equipment and supplies sector.

The company’s financial metrics indicate a price-to-earnings ratio of -3.71, suggesting that it is currently not generating profits. However, VentriPoint’s innovative approach to heart disease diagnostics positions it as a potential leader in the industry, with the potential for future growth and profitability.

VentriPoint Diagnostics Ltd. remains committed to advancing diagnostic technology and improving patient outcomes. For more information about the company and its offerings, interested parties can visit their website at www.ventripoint.com . As the company continues to develop its technology and expand its market presence, it remains a key entity within the health care equipment and supplies sector.